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Abstract: Diabetic nephropathy (DN) is associated with an increased morbidity and mortality, 
resulting in elevated cost for public health systems. DN is the main cause of chronic kidney disease 
(CKD) and its incidence increases the number of patients that develop the end-stage renal disease 
(ESRD). There are growing epidemiological and preclinical evidence about the close relationship 
between inflammatory response and the occurrence and progression of DN. Several anti-
inflammatory strategies targeting specific inflammatory mediators (cell adhesion molecules, 
chemokines and cytokines) and intracellular signaling pathways have shown beneficial effects in 
experimental models of DN, decreasing proteinuria and renal lesions. A number of inflammatory 
molecules have been shown useful to identify diabetic patients at high risk of developing renal 
complications. In this review, we focus on the key role of inflammation in the genesis and 
progression of DN, with a special interest in effector molecules and activated intracellular pathways 
leading to renal damage, as well as a comprehensive update of new therapeutic strategies targeting 
inflammation to prevent and/or retard renal injury. 
Keywords: inflammation; type 2 diabetes; diabetic nephropathy; chronic kidney disease; 
inflammation; drugs; and therapy 
 
1. Introduction 
Diabetic nephropathy (DN) is a common complication of type 1 and type 2 diabetes (T1DM and 
T2DM). DN is the leading cause of chronic kidney disease (CKD), increasing the morbidity and 
mortality of diabetic patients [1]. DN morphological abnormalities include early glomerular 
hypertrophy, glomerular basement membrane (GBM) thickening, podocyte depletion, mesangial 
matrix expansion, and tubular damage. In later phases, renal alterations include glomerulosclerosis 
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and tubulointerstitial fibrosis, clinically characterized by the loss of renal function with or without 
albuminuria and progression to end-stage renal disease (ESRD) [2,3]. 
DN is a multifactorial disease characterized by the complex interaction of hemodynamic and 
metabolic factors, including high glucose blood levels, advanced glycation end-products (AGEs), and 
activation of the renin–angiotensin–aldosterone system (RAAS) [4]. Therefore, the current 
management of diabetic patients focuses on tight glycemic control and antihypertensive/lipid-
lowering therapies; however, these interventions do not prevent the progression of CKD in a large 
proportion of patients [5,6]. For that reason, the search for novel therapeutic approaches against DN 
is an area of paramount importance.  
Inflammation is a mechanism activated in response to harmful conditions to maintain tissue 
homeostasis and integrity. However, chronic activation of the inflammatory response triggers 
collateral injurious effects [7]. Although hyperglycemia, oxidative stress, and RAAS activation are 
the driving forces for renal damage associated with diabetes, numerous pieces of evidence point out 
the key role of inflammation in the development and progression of diabetic complications [8] (Figure 
1). Thus, in the last years, the modulation of the inflammatory response has emerged as a potential 
strategy to decrease diabetic kidney disease [9,10]. These therapeutic approaches are based on 
inhibition of, adhesion molecules, chemokines, cytokines, immune cells, and intracellular signaling 
pathways involved in the inflammatory response. This manuscript aims to review the role of 
inflammation in DN-mediated kidney injury, with a special focus on immune cells, 
immunoinflammatory mediators, and cell signaling pathways, as well to fully address novel anti-
inflammatory therapies to prevent and/or retard the progression of renal damage in this pathological 
context. 
 
Figure 1. Mechanisms involved in inflammation, tissue injury and progression of renal damage in 
diabetic nephropathy (DN). 
2. Mechanisms Triggering DN-Associated Inflammation 
In DN, hyperglycemia leads to the expression of inflammatory mediators (chemokines and 
cytokines) by injured glomerular and tubular cells, contributing to renal damage by different 
mechanisms: mesangial proliferation, podocyte/tubular damage and leukocyte infiltration [11,12]. 
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These proinflammatory molecules also induce extracellular matrix deposition and 
differentiation/proliferation of myofibroblast through different signaling pathways, such as NF-κB, 
JAK/STAT, TGFβ/Smad, among others [13–15]. 
In DN, both hyperglycemia and hemodynamic abnormalities elicit glomerular hyperfiltration, 
mechanical stress, glycocalyx dysfunction, and endothelium activation [4,16]. Consequently, 
endothelial cells upregulate the expression of adhesion molecules, glycosaminoglycans and 
chemokines, which are involved in the infiltration of leukocytes toward the renal interstitium [17]. 
Chemokines promote the activation of integrins by leukocytes, allowing the interaction of these cells 
with the endothelial adhesion molecules [18]. This interaction results in the adhesion of inflammatory 
cells to the endothelium and further transmigration to other tissues [19]. Once infiltrated in the 
inflammatory foci, leukocytes promote renal damage by two different mechanisms: (1) direct 
interaction and activation of glomerular and tubular cells, and (2) releasing chemokines, cytokines, 
and profibrotic factors that activate stromal renal cells. Then, these stromal renal cells secrete 
additional chemokines promoting further infiltration of leukocytes. All these events amplify the 
inflammatory response in a positive feedback loop that enhances renal damage [9,12]. Inflammatory 
molecules induce vascular remodeling, endothelial dysfunction, extracellular matrix deposition, 
mesangial proliferation, podocyte and tubular death, GBM thickness and glomerulosclerosis, which 
are hallmarks of diabetic kidney disease [2,20]. 
There is a close and retroactive relationship between oxidative stress and inflammation in DN 
[21–24]. Thus, experimental models of DN have demonstrated that the production of cytokines is 
partially promoted by hyperglycemia-mediated oxidative stress [25,26]. Studies in patients have 
demonstrated that glucose administration increased IL-6 or IL-18 plasma concentration, an effect that 
was reduced with the antioxidant glutathione [27]. In this line, a strong and independent relationship 
between oxidative stress markers and cell adhesion molecules (ICAM-1) and other inflammatory 
mediators (CCL2) was found in T1DM and T2DM patients [28,29]; however, vitamin E administration 
abolished this association [30–32]. The induction of proinflammatory factors by oxidative stress can 
occur through the activation of NF-κB and the activator protein-1 (AP-1), two key transcription 
factors mediating inflammatory response during DN, as we will fully describe in the next sections of 
this review [25,33–35].  
3. Immune Cells and DN 
Cells of the innate and adaptive immune response are involved in DN. In the next section, we 
will fully address the role of these immune cells in this clinical condition. 
3.1. Macrophages 
Macrophages are early recruited during the genesis of renal injury in diabetes and are also 
associated with the progression of the disease [36,37]. Macrophage infiltration is mediated by several 
chemokines, including chemokine-CC motif ligand 2 (CCL2), CCL5, CXCL1, CXCL16, and CXCL10 
chemokines receptors and adhesion molecules (ICAM-1 and E-selectin) [38–40].  
Macrophages produce different molecules triggering renal injury in DN, including reactive 
oxygen species, proinflammatory cytokines (IL-1β and TNF-α), chemokines (CCL2), factors of the 
complement system, and metalloproteinases [38,39,41]. Macrophage activation and accumulation 
positively correlate with hyperglycemia, glomerular/tubular damage, endothelial activation, and 
decline of renal function [36]. Thus, macrophages induce proteinuria and glomerulosclerosis [42]. In 
a model of progressive DN, renal macrophage infiltration correlated with renal chemokine 
expression, such as CCL2, migration inhibitory factor, osteopontin, and monocyte colony-stimulating 
factor [36]. Moreover, preclinical studies in models of DN showed that glomerular and interstitial 
macrophages positively expressed activation markers such as sialoadhesin and inducible nitric oxide 
synthase [38]. Macrophages also release profibrotic mediators (PDGF and TGF-β) that elicit 
mesangial-mediated fibronectin production and fibroblast/mesangial proliferation [43].  
Lipid abnormalities are frequent in diabetic patients. Hyperlipidemia induces macrophage-
derived foam cells formation. Thus, macrophages exposed to serum samples from T2DM patients 
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were transformed into foam cells [44]. An increased presence of foam cells was observed in the renal 
glomerulus of diabetic mice fed on a hypercholesterolemic diet [45]. Lipid lead macrophages release 
a high number of cytokines, thus contributing to the inflammatory process.  
In the early and middle stages of DN, infiltrated macrophages are derived from recruited 
monocytes, which undergo polarization/differentiation towards a proinflammatory M1 phenotype 
rather than anti-inflammatory M2 phenotype. Indeed, macrophages isolated from diabetic kidneys 
showed the greatest expression of M1 markers (Ly6C, IL-6 and CCR2) than M2 markers (CD206 and 
CD163) [41]. In DN, polarization toward the M1 phenotype is related to the activation of several 
intracellular signaling pathways (NF-κB, JAK/STAT, SREBP-1) in response to TNF-α, glucose, and 
AGEs production [46,47]. The M1 macrophages produce TNF-α, accelerating the inflammatory 
process in DN [48]. Moreover, M1 macrophages directly disturb podocyte integrity [41]. Specific 
deletion of cyclooxygenase-2 in macrophages regulated the process of macrophage differentiation in 
DN [49]. The heterogeneity of macrophage phenotype and function ultimately determines the 
outcome of DN [50]. M2 macrophages secrete IL-10, with potent anti-inflammatory effects, such as 
the activation of HO-1 and the inhibition of TNF-α production [51]. Therefore, induction to the M2 
phenotype has been one of the key goals of immune-based treatments for DN.  
3.2. Dendritic Cells 
Dendritic cells (DCs) are mononuclear phagocytes that reside in many organs, including the 
kidney. These antigen-presenting cells show different phenotypes and functions depending on the 
local microenvironment. In the kidney, DCs act as a bridge between innate and adaptive immunity 
[52] and participate in the tubulointerstitial immune cell cross-talk during the progression of DN 
[53,54]. Matured DCs produce cytokines and costimulatory molecules and activate T lymphocytes 
and renal macrophages, thus mediating inflammation and kidney damage. Experimental 
immunomodulatory strategies, such as mesenchymal stem cell transplantation and Fms-like tyrosine 
kinase 3 inhibitor, reduce the population and maturation of DCs and ameliorate inflammation and 
CKD [55,56]. However, there is still limited information about the distinct functions of DCs’ subsets 
in the pathogenesis of DN.  
3.3. T Lymphocytes 
Several studies have demonstrated the increased presence of activated CD4+, CD8+ T cells in 
renal interstitium of patients with diabetes [57]. These T cells release IFN-γ and TNF-α, as noted in 
diabetic mice, thus contributing to the promotion of inflammation by activation of macrophages and 
endothelial cells [57]. Specifically, CD4+T cells also enhance fibrosis by activating fibroblasts [58]. The 
number of CD4+ T cells in diabetic kidneys correlated positively with proteinuria levels [57]. In the 
same line, induction of DN in mice without T and B lymphocytes (Rag1-/- mice) showed that 
lymphocytes activate glomerular macrophages, induce podocyte injury, and increase albuminuria 
[59]. Pharmacological inhibition of T-cell activation with CTLA4-Fc abatacept also reduced 
albuminuria in mice with DN [60].  
CD4+ T cells can differentiate into different cell-subtypes, including T-helper subsets 
(Th1/Th2/Th17) and regulatory T cells (Tregs). Th1 and Th17 cells have been specifically associated 
with renal damage in DN. These inflammatory cells release chemokines in response to IL-1𝛽, IL-6, 
and TGF-𝛽, which are frequently found in diabetic kidneys [48]. Targeting Th17 cells by 
mycophenolate mofetil attenuated albuminuria and tubulointerstitial fibrosis in mice with DN [61]. 
On the other hand, depletion of Tregs with anti-CD25 mAb exacerbates diabetic-associated renal 
injury in mice, whereas the adoptive transfer of Tregs had the opposite effect [62]. 
3.4. B Lymphocytes 
B-cells are found in the glomeruli of diabetic patients and experimental models of DN, 
suggesting the involvement of these cells in this pathological setting [57,59]. The pathogenic role of 
B-cells in DN is based on their capacity to produce immunoglobulins (predominantly IgG and IgM 
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isotypes) against neoantigens formed as a consequence of diabetes, such as AGE–LDL, 
malondialdehyde-LDL and oxidized-LDL [63,64]. These immunoglobulins activate specific Fc 
receptors and the complement system [65,66]. In this line, increased IgG and C3 glomerular deposits 
were observed in experimental DN [36,59]. Moreover, the presence of IgG in renal biopsies from 
diabetic patients was associated with worse outcomes [67]. Interestingly, diabetic mice lacking IgG 
Fc receptors had reduced renal damage, inflammation, and fibrosis [68]. Therefore, strategies aimed 
to reduce Fc receptor signaling in DN may be of interest. 
3.5. Mast Cells 
Mast cells are myeloid-derived immune cells with an important role in many autoimmune and 
inflammatory diseases. Mast cells infiltrate the diabetic kidney in all stages of the disease, and their 
number and degranulation levels increase in line with the progression of the disease in patients 
[69,70]. The anaphylatoxin C3a triggers mast cells activation and chemotaxis toward inflammatory 
foci, and probably may be responsible for their recruitment in DN [71]. Mast cells are also able to 
promote renal fibrosis via SCF/c-kit signaling pathway and induce tubular interstitial injury by 
increasing the production of proteases and inflammatory mediators, such as chymase, renin, TGF-β1 
and TNF-α [70,71]. Inhibition or reduction of chymase-positive mast cells, ameliorated albuminuria 
in db/db mice [72]. A clinical trial with the chymase inhibitor BAY1142524 in patients with DN is now 
completed, but no results have been yet posted (NCT03412006). 
3.6. Neutrophils 
There is limited information about the possible role of neutrophils in DN. Nevertheless, 
neutrophils from T1DM and T2DM patients have a higher capacity to adhere to endothelium as 
compared to those from normo-albuminuric patients [73]. Additionally, neutrophils release high 
amounts of ROS and TNF-α, thus promoting endothelial damage and, therefore, accelerate DN-
mediated renal damage [74,75]. Also, increased neutrophil to lymphocyte ratio has been associated 
with albuminuria in diabetic patients [76]. 
4. Inflammatory Mediators in DN 
As previously described, cell adhesion molecules, chemokines and cytokines play a key role in 
renal damage associated with DN. In this section, we will fully address the key role of these molecules 
in DN-mediated renal damage as well as different therapeutic approaches targeting these 
proinflammatory molecules in this pathological condition (Figure 2). 
4.1. Cell Adhesion Molecules 
Cell adhesion molecules (CAMs) are implicated in leucocyte trafficking between blood and 
tissues. These molecules mediate leukocyte rolling on vascular endothelial cells and tightly adhere 
them to the endothelium to be further recruited to the inflammatory foci [77]. Therefore, CAMs 
mediate the interaction between leukocytes and endothelial cells, playing a key role in DN. There are 
many CAMs involved in the onset and development of diabetes-associated renal injury. 
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Figure 2. Cytokines and intracellular signaling pathways activating inflammation in DN. This is a 
simplified view since there are tremendous connections between the different pathways, indicating 
the complexity of the inflammatory response. 
Intercellular adhesion molecule 1 (ICAM-1) is a cell adhesion molecule that interacts with 
macrophage-1 antigen (Mac-1) and lymphocyte function-associated antigen-1 (LFA-1). ICAM-1 
expression is upregulated in endothelial cells of glomerular and interstitial capillaries by 
shear/oxidative stress and cytokines [78–80]. Plasma ICAM-1 levels are increased in T1DM and T2DM 
patients, being associated with urinary albumin excretion rate or microalbuminuria [81,82]. A recent 
meta-analysis showed that the rs5498 polymorphism is a risk factor for DN in Caucasian T1DM 
patients [83]. ICAM-1 gene deletion or the use of an anti-ICAM-1 antibody reduced macrophage 
infiltrate as well as decreased mesangial proliferation, glomerular Col IV expression and albuminuria 
in different experimental models of diabetes [40,84].  
Vascular cell adhesion molecule-1 (VCAM-1) was also found elevated in renal vascular 
endothelium and infiltrating leukocytes in diabetic kidneys. In T2DM patients, increased levels of 
VCAM-1 correlated with albuminuria [85] and were identified as a prominent mortality risk factor 
[86]. 
Vascular adhesion protein-1 (VAP-1) is an endothelial cell-surface oxidase that induces oxidative 
stress and cellular toxicity [87]. VAP-1 plasma levels are elevated in diabetic patients, being associated 
to eGFR decline and albuminuria [88,89], and may be related with cardiovascular and cancer 
mortality risk of these patients [89,90]. A recent phase II clinical trial in diabetic and CKD patients 
showed that the administration of the oral VAP-1 inhibitor ASP8232 in combination with RAS 
blockade, delayed progression of renal damage [91].  
Galectin-3 is a β-galactoside binding lectin that has been related to DN because acts as a receptor 
for AGEs [92]. Circulating galectin-3 levels increased in line with loss of renal function and was 
associated with cardiovascular events and mortality in two clinical cohorts (4D and LURIC) [93]. The 
galectin-3 antagonist GCS-100 was used in diabetic patients with CKD, but results has not been yet 
posted (NCT02312050). 
αVβ3 integrin is expressed by the glomerular endothelium and podocytes [94]. Increased 
expression of the αVβ3 integrin and its ligand (vitronectin) has been observed in kidneys from 
diabetic rats [95]. Blockade of the αVβ3 integrin using a monoclonal antibody decreased proteinuria 
and early histologic changes of diabetic nephropathy in pigs (Table 1) [96]. Moreover, the use of αvβ3 
Integrin antagonist (MK-0429) in ZSF1 rats decreases proteinuria, renal fibrosis and collagen 
accumulation in diabetic damaged kidneys [97]. An ongoing clinical trial evaluates the effect of a 
αVβ3 integrin antibody in patients with DN, although no results have been published 
(NCT02251067). 
Selectins have been also implicated in DN, and E-selectin is the most studied one in this 
pathological context [98]. In diabetic mice, E-selectin expression is induced by IL-1β or TNF-α levels 
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being observed in glomeruli, mainly located in endothelial cells [99], and this expression was 
correlated with the amount of CD14 positive interstitial cells [98]. In T1DM patients, increased E-
selectin plasma levels have been reported, correlating with the decline of renal function and 
cardiovascular risk [100]. In the case of P-selectin, T2DM patients showed increased levels of P-
selectin and associated to the severity of disease [101], an effect that was reduced with the 
combination of ARB olmesartan and the ACEi imidapril [102]. 
4.2. Chemokines 
Chemokines are small soluble signaling proteins that can be involved in glomerular and 
tubulointerstitial inflammation. These molecules are released by resident renal cells recruiting and 
activating circulating leukocytes [103].  
Several chemokines (CCL2, CCL5, CCL11, CXCL5, CXCL8, CXCL9, CXCL12, CX3CL1) and 
chemokine receptors (CCR2, CCR5, CXCR4, CX3CR1) were found to be elevated in kidneys of 
diabetic mice/rats and in renal biopsies from DN patients [104,105]. In diabetic kidneys, these 
chemokines and their cognate receptors are expressed by tubular cells and podocytes, as well as 
infiltrating leukocytes [104,106]. The renal expression of these proteins is progressively increased in 
line with macrophage infiltration, proteinuria and renal function decline [104]. Consequently 
chemokine urinary levels, such as CCL2, CXCL5, CXCL8 and CXCL9, are significantly elevated in 
later phases of diabetic kidney disease [107,108]. A study in patients with DN showed that urinary 
levels of CXCL9 and CXCL11 mRNA levels correlated with the eGFR decline [109]. CXCL12/SDF-1-
α plasma levels were useful for predicting the progression of renal dysfunction in patients with 
coronary artery disease [110]. Therefore, urinary and/or systemic analysis of chemokine levels may 
be a useful clinical tool for patient risk stratification.  
The expression of chemokines is directly upregulated by the diabetic harmful environment. 
Thus, CCL2 is activated by high glucose and AGE via NF-κB in mesangial cells [111]. The role of 
CX3CL1/CX3CR1 axis in DN has been recently reviewed [112]. CX3CL1 (fractalkine) was found in 
glomerular and peritubular capillaries, whereas CX3CR1 is expressed by T lymphocytes and 
activated monocytes/macrophages [113]. Experimental data indicated an important role of this axis 
in the progression of DN, as well as a direct relation with RAAS [113]. In DN, CX3CL1 pathogenic 
effects include mesangial cell proliferation via cellular reactive oxygen species (ROS) generation and 
activation of MAPK signaling pathway [114], extracellular matrix accumulation [115] and podocyte 
apoptosis [116]. Moreover, the inter-regulation of CX3CL1 and MMP2 mediates the crosstalk between 
monocytes and mesangial cells in the context of DN [117]. 
In experimental models of DN, targeting chemokines and its receptors reduced renal 
inflammation and the subsequent pathological consequences, including oxidative stress, fibrosis, and 
glomerular damage [36,118]. There are many strategies to modulate the action of chemokines and its 
receptors, such as the use of specific chemokines receptor antagonists or chemokine inhibitors. For 
example, the blockade of CXCL12 by the specific inhibitor NOX-A12 diminished podocytopenia and 
glomerulosclerosis independently of glycemic control or glomerular macrophage infiltration [119]. 
The pharmacological inhibition of CXCR4 in diabetic rats with the small molecule inhibitor AMD3100 
increased albuminuria, reduced VEGF excretion, and accelerated tubular epithelial cell death, 
indicating that CXCR4 may be a promoter of renal tubular cells survival [106]. In diabetic mice, the 
injection of a recombinant murine CXCL10 reduced albuminuria, mesangial and peritubular cell 
expansion, and glomerular hypertrophy [120]. In experimental diabetes, several CCR2 antagonists 
(such as propagermanium, CCX140-B, RO5234444, RS102895 or RS504393) selectively blocked CCL2-
dependent monocyte activation and provided beneficial metabolic effects against DN-mediated 
podocyte injury and albuminuria [121–124]. A new area of interest is the inhibition of multiple 
chemokines at the same time. For example, dual inhibition of CCL2 and CXCL12 with specific RNA 
enantiomers (CCL2-specific mNOX-E36 and the CXCL12-specific NOX-A12) had additive effects 
against diabetic-associated renal injury [125].  
These positive experimental data have been confirmed in human clinical trials. Thus, the CCR2 
inhibitor CCX140-B administered for up 52 weeks reduced urinary albumin/creatinine ratio (UACR) 
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in patients with DN [126]. In the same line, inhibition of CCL2/CCR2 signaling with emapticap pegol 
(NOX-E36) for up 12 weeks showed beneficial effects on urine albumin levels and reduced high blood 
glucose levels in T2DM patients with residual albuminuria on RAAS blockade [127]. However, no 
protective effects were observed during 12 weeks of treatment with F-04634817, a dual chemokine 
CCR2/5 receptor antagonist, in T2DM patients that were on ARBs and/or ACEi therapy [128]. In that 
study, patients had high levels of albuminuria and low eGFR at baseline, suggesting that the 
beneficial effects of chemokine targeting may be more effective at earlier stages of DN. 
Table 1. Selected preclinical studies targeting inflammatory mediators in DN. 
Target Diabetic Model Strategy Category Conclusion Ref. 
CAM 






Prevents glomerular mononuclear cell 
infiltration.  
[84] 






Attenuates proteinuria and renal histological 
changes. 
[96] 
ZSF1 rats MK-0429 αVβ3 inhibitor Reduces proteinuria and renal fibrosis [97] 
Chemokines 
 




Increases albuminuria and accelerated tubular 
cell death. 
[106] 
db/db mice NOX-A12 
CXCL12 






Reduces mesangial matrix expansion, 
albuminuria, and glomerular hypertrophy. 
[120] 
iNOS-Tg mice Propagermanium 
CCR2 
antagonist 
Decreases mesangial matrix expansion and 
macrophage infiltration. 
[121] 
db/db mice RS504393 
CCR2 
antagonist 
Ameliorates inflammation, oxidative stress, and 
fibrosis. 
[123] 
db/db mice CCX140-B 
CCR2 
antagonist 
Reduces albuminuria, glomerular hypertrophy 
and increases podocyte number. 
[124] 
Cytokines 





Decreases albuminuria. [129] 
KK-A(y) mice Etanercept 
TNF-α 
inhibitor 
Improves albuminuria, macrophage infiltrate 
and CAM expression. 
[130] 
SD rats + STZ  
(65 mg/kg) 
Tocilizumab IL-6 inhibitor 
Decreases albuminuria, oxidative stress, 
inflammation. 
[131] 




Improves kidney injury markers and attenuates 
decline of eGFR. 
[132] 
db/db, and 
Akita mice; STZ  





Prevents fibrosis, podocytes loss, tubular 








Ameliorates renal function, macrophage 
infiltration and podocyte loss. 
[134] 
Wistar rats + 
STZ (70 mg kg) 
Anti-IL-20  
antibody IL-20 inhibitor 
Reduces glomerular area and improves renal 
functions. [135] 
db/db mice ISO-1 MIF inhibitor 
Decreases albuminuria, fibrosis and 
inflammation. 
[136] 





Decreases UACR, serum BUN and creatinine. [137] 
Abbreviations: CAM: cell-adhesion molecules; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; STZ: 
streptozotocin; SD: Sprague Dawley; ZSF1: Zucker fatty/spontaneously hypertensive heart failure F1 hybrid. 
4.3. Cytokines 
4.3.1. TNF-α 
TNF-α influences the recruitment and activation of leukocytes, exacerbating DN-associated 
inflammatory response [11,138]. In diabetic kidneys, TNF-α and its receptors TNFR1 and TNFR2, are 
involved in the synthesis of cytokines, chemokines, growth factors, extracellular matrix proteins and 
mediate a wide variety of cytotoxic effects on podocytes, mesangial, endothelial and epithelial cells 
[138–140]. Moreover, the serum and urinary levels of TNF-α are increased in patients with DN 
compared to healthy controls and there is a close relationship with albuminuria in diabetic patients, 
suggesting TNF-α as a potential prognostic biomarker in DN [140–142]. TNF-α receptors can be shed 
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from the extracellular membrane as two soluble proteins, named sTNFR1 and sTNFR2. These 
molecules were able to predict the loss of eGFR and ESRD in T1DM and T2DM patients [140,143,144]. 
In a recent study, 194 circulating inflammatory proteins were analyzed in T1DM and T2DM subjects 
from three independent cohorts, identifying an extremely robust kidney risk inflammatory signature 
(KRIS), consisting of 17 proteins of the TNFR superfamily members that were associated with a 10-
year risk of ESRD [10]. Therefore, these proteins may be new prognostic biomarkers for progressive 
DN. Some treatments, such as pentoxifylline and ACEi, reduced the TNF-α renal expression in mice 
and patients with diabetes [139,145]. In those studies, the reduction of TNF-α levels was directly 
associated with the decline of albuminuria, highlighting a pathogenic role of TNF-α in DN. In the 
PREDIAN trial, patients with T2DM and CKD (stages 3–4) were treated with pentoxifylline in 
addition to RAAS inhibitors for 2 years, resulting in a smaller decrease in eGFR and greater reduction 
of residual albuminuria, coinciding with a marked reduction in urinary TNF-α [146]. Recently, new 
clinical trials have proposed pentoxifylline as a possible therapeutic agent in this pathological context 
(NCT03664414; NCT03625648). There are strategies specifically targeting TNF-α in this pathological 
context. A soluble TNF-α antagonist (TNFR:Fc) reduced urinary TNF-α excretion as well as renal 
damage associated with DN [147]. Similar results were observed with the monoclonal antibody 
infliximab, a TNF-α inhibitor that reduced albuminuria in experimental diabetes [129]. Etanercept, a 
soluble TNFR2 fusion protein targeting TNF-α-TNFR2 pathway, reduced the levels of cell adhesion 
molecules, macrophage renal infiltrate, and albuminuria in diabetic mice [130]. However, to our 
knowledge, no clinical studies are targeting TNF-α in the context of renal complications of diabetes. 
4.3.2. IL-6 
Il-6 is a cytokine that plays a key role in inflammatory pathologies. A recent meta-analysis in 
patients with DN revealed the essential role of different polymorphisms of IL-6 such as rs1800795, 
rs1800796, and rs1800797 in the development and progression of DN [148]. The IL-6–174 G allele 
increased the risk to develop renal complications in T2DM patients [149]. These pieces of evidence 
suggest that IL-6 may be related to DN. Increased IL-6 urinary levels were found in patients with DN, 
mainly in those with worse renal outcomes [150]. Some therapies have been developed to inhibit IL-
6 signaling pathway [151]. Tocilizumab, a humanized antibody that blocks the IL-6 receptor (IL-6R), 
attenuated the histopathological changes induced by streptozotocin (STZ) in rats, by decreasing 
inflammation and oxidative stress [131]. Clinical trials provided metabolic beneficial effects of anti-
TNF-α agents (infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol) or IL-6 
inhibitor (tocilizumab) on HbA1c, insulin resistance and insulin sensitivity in T2DM patients with 
psoriasis [152] or rheumatoid arthritis [153]. 
4.3.3. IL-1β 
Interleukin-1β (IL-1β) is one of the most potent molecules of the innate immune system 
implicated in macro- and micro-vascular complications of diabetes [154–156]. This cytokine is highly 
produced by macrophages and triggers the production of other secondary proinflammatory 
mediators by renal cells [157]. Indeed, IL-1β induced tubulointerstitial fibrosis throughout the 
activation of the MYC transcription factor, with further dysregulation of glycolysis and matrix 
production [158]. Several studies described that IL-1β causes endothelial cell damage in resistance 
arteries and identified its deleterious effect due to the NADPH oxidase activation [159,160].  
Therapeutics approaches have targeted IL-1β in diabetes. For example, in uninephrectomized 
db/db mice, an anti-IL-1β antibody reduced fibrosis, podocyte injury, and progressive decline of 
eGFR[132]. In the clinical field, the studies analyzed the role of IL-1β blockade in renal disease are 
not conclusive. In the CANTOS study (Canakinumab Anti-inflammatory Thrombosis Outcome 
Study), the blockade of IL-1β with canakinumab diminished inflammatory markers (hsCRP and IL-
6) and the cardiovascular risk in atherosclerosis patients, but did not reduce the incidence of diabetes 
[161,162]. The treatment with canakinumab did not show substantive benefits on eGFR, serum 
creatinine, and UACR [162]. On the other hand, Cavelti-Weder et al. showed that the treatment with 
gevokizumab, a novel human-engineered monoclonal anti-IL-1β antibody, improved glycemia by 
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restoring insulin production/action and reduced inflammation in patients with T2DM [163]. Another 
clinical trial in T2DM patients showed that the IL-1β -receptor antagonist anakinra improved 
glycemia and β-cell function and reduced systemic inflammatory markers [164]. The new IL-1β 
inhibitor rilonacept reduced systemic inflammation in patients with CKD [165], but not in T1DM 
patients [166]. All these results showed the key role of IL-1β in the development and progression of 
diabetic disease, but new studies are needed to confirm the clinical significance of this finding.  
4.3.4. IL-18 
Interleukin-18 (IL-18) is a member of the IL-1 cytokine family activated by inflammasome [167] 
that induces the expression of another cytokines and proinflammatory genes associated with 
apoptosis, oxidative stress, angiogenesis and cellular adhesion, such as NOX-4, p53, Il-8, TNF-α, 
VEGF and ICAM-1 [167–169]. IL-18 expression is upregulated by activation of the MAPK signaling 
pathway in tubular epithelial cells of diabetic subjects [170]. IL-18 increases the maturation of T 
lymphocytes and natural killer cells, as well as the production of other proinflammatory cytokines in 
obesity-induced systemic inflammation [171]. Among the different cytokines involved in DN, IL-18 
seems to be the most specifically associated with these metabolic and cardiovascular risk factors 
[172,173]. In renal biopsies of diabetic patients, IL-18 levels were found mainly increased in proximal 
tubular epithelial cells [170]. IL-18 has been described as a good serum and urinary predictive marker 
for DN [170,173]. Moreover, urinary levels of IL-18 were positively correlated with albuminuria and 
kidney injury progression in T2DM individuals, suggesting a close relationship with disease 
progression [142,174,175]. Two studies have analyzed the efficacy of GSK1070806, a humanized 
IgG1/kappa antibody against IL-18 in obese and T2DM patients, but there are no studies performed 
in DN [176,177]. 
4.3.5. IL17A 
IL-17A is a cytokine produced by multiple cell types, including CD4+αβ T cells, γδ T cells, 
natural killer cells, neutrophils, macrophages, dendritic cells, lymphoid tissue inducer cells, mast 
cells and plasma cells [178]. IL-17 proteins, including IL-17A and IL-17F, interact with its receptors 
(IL-17RA–IL-17RE) and trigger downstream signaling pathways associated with inflammatory 
response, such as NF-κB, and oxidative stress [178,179]. IL-17A has been involved in the pathogenesis 
of immune and inflammatory diseases, including cardiovascular and renal diseases [178,180]. 
Previous studies described that Treg/Th17 ratio in T1DM patients was dysregulated, and those 
patients with reduced β-cell function showed increased levels of IL-17A+ in comparison with the 
number of Tregs, CD4+ T cells, and CD8+ T cells [181,182]. Recent studies in diabetic patients 
demonstrated that serum levels of IL-17A and IL-2 (Th17-associated cytokines) were increased when 
compared to healthy individuals [183,184].  
In experimental models of DN, there are opposite results about the role of IL-17 in the renal 
diabetic pathology [185]. The gene blockade of IL-17A in mice increased the severity of renal damage 
induced by STZ injection. In the same study, the low dose administration of IL-17A and IL-17F in 
Akita diabetic mice reduced renal damage and recovered renal function via inhibition of the STAT3 
signaling pathway [133]. Nevertheless, other reports showed opposite results, demonstrating that the 
systemic administration of IL-17A increased levels of blood pressure and inflammatory cell 
infiltration in the renal tissue in mice [186]. Moreover, other studies found increased IL-17A levels in 
serum from hypertensive patients [187]. A recent study by Lavoz et al. in BTBR ob/ob mice showed 
that the blockade of IL-17A with a neutralizing antibody improved albuminuria and renal 
pathological effects induced by diabetes [134]. Currently, some clinical trials are studying the role of 
IL-17A blockade with neutralizing antibodies such as secukinumab and ixekizumab in chronic 
human inflammatory diseases, including ankylosing spondylitis (NCT01358175; NCT01649375) 
[188], chronic plaque psoriasis (NCT01107457) [189] and psoriatic arthritis (NCT02404350) [190]. In 
the case of IL-17F, this isoform has been identified as a circulating inflammatory protein associated 
with increased risk of the progression of renal injury in T1DM and T2DM, among others [10]. 
However, there are controversial results about the serum levels of IL-17 and the severity of renal 
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damage. Interestingly, circulating IL-17A levels were diminished in T2DM patients with or without 
DN when compared with normal glucose tolerance subjects [191]. Besides, plasma and urine IL-17A 
levels were reduced in patients with advanced DN and macroalbuminuria [133]. This data is opposite 
to the results obtained in a report in patients infected with cirrhotic hepatitis C virus. In this study, 
the circulating levels of IL-17A were increased in T2DM cohort [192]. Due to these controversial 
results, more studies about the role of IL17 signaling pathways in DN are needed.  
4.4. Other Cytokines/Proinflammatory Proteins in DN 
Among several proinflammatory proteins involved in the development and progression of DN 
is also the cytokine IL-8, which mainly attracts neutrophils and induces oxidative stress, favoring 
vascular permeability and endothelial damage in the diabetic kidney [193,194]. Genetic 
polymorphism of IL-8 (IL8-rs4073) showed a strong association in Asian people with DN [195]. Other 
studies showed elevated circulating IL-8 levels in T2DM patients [193]. A bioinformatic analysis in 
endothelial precursor cells isolated from patients with T2DM showed that IL-8 and CXCL1 genes 
were the most expressed molecules in diabetic samples [196]. 
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the TNF 
superfamily. Recently, the expression of TWEAK and its canonical receptor Fn14 was found 
dysregulated in the ZSF1 DN rat model, correlating with proteinuria and inflammation (CCL2 levels) 
[197]. Serum sTWEAK levels gradually decreased in T2DM patients in line with DN progression 
[193]. In another study, a negative correlation has been described between TWEAK and YKL-40, a 
potential biomarker for early diagnosis of incipient DN [198]. In a clinical trial in T2DM hypertensive 
patients with proteinuria, the combined therapy with RAAS blockers and calcium channel blockers 
normalized proteinuria, sTWEAK and PTX3 levels [199]. 
IL-20 is a pleiotropic cytokine associated with the inflammatory response that is expressed in 
the epithelium, endothelial cells, and monocytes/macrophages and is related to renal damage 
[200,201]. Hyperglycemia, ROS and TGF-β1 upregulated IL-20 mRNA/protein expression in 
podocytes of STZ-diabetic mice [135]. Deficiency in IL-20R1 and blockade of IL-20 with anti-IL-20 
mAb 7E reduced UACR, mesangial cell expansion, and podocyte apoptosis in experimental diabetes. 
In the same study, experiments in cultured podocytes stimulated with IL-20 showed an increase in 
MMP-9, CCL2, TGF-β1, and VEGF gene expression levels [135,200]. Finally, serum IL-20 levels in DM 
patients were significantly elevated compared to healthy controls [135]. 
Gremlin, a bone morphogenetic protein 7 (BMP-7) antagonist, was identified as one of the 
developmental genes differentially expressed in diabetic kidneys [202]. In DN experimental models, 
the gremlin blockade ameliorates renal damage [203], and tubular overexpression of Gremlin in 
transgenic mice aggravates glomerular and tubulointerstitial injury [204] suggesting that Gremlin 
could be a novel therapeutic target for DN. In human biopsies of DN, Gremlin expression correlated 
with the grade of tubulointerstitial fibrosis and inflammation, colocalizing with TGFβ1 
overexpression and Smad pathway activation [205]. Gremlin binds to vascular endothelial growth 
factor receptor 2 (VEGFR2) in endothelial and tubular epithelial cells, regulating the tubular epithelial 
to mesenchymal transition (EMT), and therefore, could contribute to renal fibrosis [206]. Gremlin 
activates the VEGFR2 signaling pathway in the kidney, eliciting a downstream mechanism linked to 
the renal inflammatory response [207]. Recently, VEGFR2 blockade, using a VEGFR2 kinase inhibitor, 
improved renal function, glomerular damage (mesangial matrix expansion, GBM thickening, and 
podocyte injury) and tubulointerstitial inflammation in T2DM model BTBR ob/ob [208].  
Progression of DN has been also related to migration inhibitory factor (MIF), a cytokine that 
takes part in immune/inflammatory pathological response in DN, mainly associated with 
macrophage accumulation/activation [209]. In the KORA S4 study, serum MIF levels were increased 
in db/db mice [36] and T2DM patients [210]. Besides, increased levels of CD74 (MIF receptor) have 
been also reported in clinical and preclinical reports [211]. Wang et al. described that the 
pharmacological blockade of MIF with ISO-1 in db/db mice induced a significant decrease in 
albuminuria, blood glucose levels, extracellular matrix deposition, EMT, and macrophage activation 
in damaged kidneys [136]. Moreover, the use of the MIF antagonist (p425) in STZ-induced diabetic 
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rats, decreased the loss of renal function (protein excretion, UACR, and serum BUN and creatinine 
levels) [137].  
Macrophage inflammatory protein-1 (MIP-1), a chemokine produced by macrophages after the 
recognition of pathogens, is predominantly elevated in the early stages of DN [212]. Multiplex 
analyses of urinary inflammatory proteins revealed that levels of MIP-1α and MIP-1β, along with 
other chemokines and cytokines, were significantly increased in microalbuminuric DN patients 
compared to healthy controls [213], although only IP-10 and CCL2 correlated with albumin excretion 
rate and eGFR [213].  
Other clinical trials are now targeting cytokines (IL-33) and growth factors (TGFα/β) by using 
humanized monoclonal antibodies in patients with DN (NCT04170543, NCT01113801, 
NCT01774981). 
5. Inflammatory Intracellular Signaling Pathways 
Dysregulation of several signaling pathways leads to persistent inflammation and has been 
found to be involved in the onset and progression of DN (Figure 3). 
 
Figure 3. Therapeutic compounds targeting proinflammatory intracellular signaling pathways in DN. 
5.1. Nod-Like Receptors 
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) are pattern-
recognition cytoplasmic receptors that link innate immunity, inflammation and metabolism in 
diabetes [214]. NLRs are classified into four functional categories: autophagy, signal transduction, 
transcription activation and inflammasome formation [214,215]. Nucleotide-binding oligomerization 
domain-containing protein 1 (NOD1) and NOD2 are critical members of the signal transduction 
pathway that contribute to inflammation in DN [216]. High glucose concentrations increased NOD1, 
NF-κB and IL-1β expression in cultured mesangial cells, an effect reverted with the NOD1 inhibitor 
ML130 [217]. On the other hand, NOD2 is highly expressed in renal biopsies from diabetic patients, 
correlating with the severity of the disease. In the same study, hyperglycemia activated NOD2 
expression in glomerular vascular endothelial cells, which promoted endothelial-to-mesenchymal 
transition in a MEK/ERK-mediated way [218]. Oxidative stress also activates NOD2 expression post-
transcriptionally throughout the RNA-binding protein human antigen R [219]. AGEs, TNF-α, and 
Int. J. Mol. Sci. 2020, 21, 3798 13 of 40 
 
TGF-β are also involved in NOD2 overexpression by podocytes [216]. Reduced nephrin expression 
was noted in kidney form NOD2-knockout mice with a high-fat diet/STZ-induced diabetes [216].  
The NLRP family, pyrin domain-containing protein (NLRP) is composed of NLRP1, NLRP3, 
NLRP6 and NLRC4, which are key components of different inflammasomes [215]. Inflammasome 
has been implicated in metabolic disorders such as diabetes, obesity and atherosclerosis. In particular, 
the activation of the NLRP3 inflammasome participates in the production and persistence of 
inflammatory response in DN [220]. Previous in vivo and in vitro studies showed that hyperglycemia 
increases the expression of NLRP3 and activates caspase-1, inducing the release of IL-1β and IL-18 
[221,222]. In renal tubular epithelial cells stimulated with high glucose or transforming growth factor-
β1 (TGF-β1), knockdown of NLRP3 reduced ROS production and prevented EMT by inhibiting the 
phosphorylation of Smad3, p38/MAPK and ERK-1/2 [223]. Moreover, a study in 135 diabetic subjects 
with or without DN, revealed that CASP1 mRNA expression was significantly associated with 
decreased eGFR and severity of DN [224].  
The gene blockade of NLRP3 in diabetic mice improved renal function, glomerular hypertrophy, 
glomerulosclerosis, mesangial expansion and inflammation as well as the activation of Smad3 
signaling pathway [225]. Wang et al. showed that the overexpression of renal inflammasome 
components NLRP3, apoptosis-associated speck-like protein and caspase-1 in a STZ-rat model 
caused an increase in hyperuricemia, hyperlipidemia as well as elevated levels of IL-1β and IL-18. 
Also, treatment with the flavonoid quercetin and the uric acid-lowering drug allopurinol, reduced 
the expression of these inflammatory markers and ameliorated kidney damage [226]. On the other 
hand, the use of the anti-inflammatory compounds such as cepharanthine and piperine in a rat model 
of DN ameliorated hyperglycemia and renal dysfunction, and also decreased NLRP3 and NF-κB 
expression in diabetic kidneys [227]. In the diabetic apolipoprotein E knockout (apoE-/-) mice, 
administration of PPAR-γ agonist pioglitazone downregulated the expression of AGEs, RAGE, and 
NF-κB, and also diminished NLRP3, caspase-1, IL-18, and IL-1β levels [228]. MCC950, a selective 
inhibitor of NLRP3 andM920, a broad specificity caspase inhibitor, improved renal function, GBM 
thickening, podocyte injury, renal fibrosis, and NLRP3-dependent markers in db/db mice [229,230].  
5.2. Toll-Like Receptors 
Recent studies highlight the essential role of toll-like receptors (TLRs), especially TLR2 and 
TLR4, in DN. TLRs induce renal injury and fibrosis via the NF-κB signaling pathway [231]. Therefore, 
reducing the inflammatory response associated with TLRs may provide a new therapeutic approach 
in diabetic kidney disease. In a mouse model of advanced DN, administration of the TLR4 antagonist 
CRX526 significantly decreased albuminuria, blood urea nitrogen, glomerular hypertrophy, 
glomerulosclerosis and tubulointerstitial injury, an effect related to the impairment in CCL2/CCL5 
levels, TGFβ and NF-κB activity [232]. Mixed approaches are also being tested, such as the 
administration of GIT27 (VGX-1027), a TLR4 and TLR2/6 signaling pathway modulator, that 
effectively improved insulin resistance and protected from renal injury in a db/db mice by reducing 
proinflammatory cytokine synthesis and oxidative stress [233]. Besides TLRs antagonists, several 
anti-TLR antibodies are being developed and tested. OPN305, a humanized monoclonal antibody 
against TLR2, is currently in phase II of a clinical trial that analyzes the prevention of delayed graft 
function (NCT01794663). Currently, no clinical studies are targeting TLRs signaling in diabetic 
kidney disease. 
5.3. PI3K/AKT/mTOR  
Phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/Akt/mTOR) signaling pathway regulates metabolism, proliferation, cell cycle, and protein 
expression, and its imbalance is involved in the development of obesity and diabetes [234]. However, 
the role of this pathway in DN is still controversial, suggesting the importance of discriminating the 
contribution of single PI3K isoforms in the diabetic kidney [235].  
Recent studies indicate that hyperglycemia activates PI3K/Akt/mTOR, leading to glomerular 
hypertrophy, podocyte damage, and progressive deterioration of kidney function [236,237]. Specific 
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PI3K/Akt/mTOR activation in podocytes generates proteinuria and mesangial cell expansion [238]. 
Inhibition of this pathway with rapamycin decreases macrophage infiltration and CCL2 release [239]. 
Furthermore, in a mouse model of diabetes, the treatment with mangiferin reduced IL-6, TNF-α, and 
Il-1β expression by inhibiting PTEN/PI3K/Akt pathway [240]. 
On the other hand, treatment with the peptide hormone Elabela activated PI3K/Akt/mTOR and 
reduced renal inflammation in diabetic mice by decreasing CCL2, ICAM-1, and TNF-α production 
[241]. In the same line, an engineered partial agonist of fibroblast growth factor-1 (FGF1ΔHBS) showed 
antioxidative effects and anti-inflammatory activities in db/db mice and also reduced oxidative stress 
and proinflammatory gene expression in podocytes challenged with high glucose by activating 
PI3K/Akt signaling [242]. Resveratrol has also shown to prevent experimental DN by regulating 
PI3K/Akt components in kidney tissue [243]. Likewise, in HK-2 tubular cells under high glucose 
conditions, treatment with the flavonoid apigenin reduced the release of TNF-α, IL-1β, and IL-6 via 
PI3K/Akt. The PI3K/Akt inhibitor LY294002 also reversed TNF-α reduction in these cells [244]. 
Moreover, in an experimental model of DN in rats, the treatment with emodin reduced IL-6 and TNF-
α expression by the activation of PI3K/Akt/GSK-3β pathway [245]. Although several PI3K inhibitors 
have been approved for clinical use against malignant hematopoietic diseases, none of these drugs 
have been tested so far in the treatment of human diabetes mellitus and its complications [235]. 
5.4. Nuclear Factor-κB 
NF-κB (nuclear factor-kappa B) is a ubiquitous transcription factor that modulates the 
expression of chemokines, cytokines, and adhesion molecules. Inhibition of NF-κB has been 
addressed through the use of molecules that target receptors, upstream activating kinases, protein 
degradation, adapter molecules, nuclear translocation, and DNA binding [246]. Numerous studies 
focus on the potential beneficial effects of NF-κB inhibition on the pathophysiological processes 
associated with DN [247]. This is the case of celastrol, a pentacyclic triterpenoid isolated from 
Tripterygium wilfordii and Celastrus regelii root extracts, which has shown beneficial effects on insulin 
resistance, body weight, renal injury, proinflammatory cytokine levels and mesangial matrix cell 
expansion through NF-κB inhibition [248]. In another study, intraperitoneal administration of miR-
451 reduced NF-κB activity and improved microalbuminuria, glomerular damage and blood glucose 
levels in a DN animal model [249]. The inhibition of NF-κB by berberine (alkaloid of the isoquinoline 
family isolated from Cortex phellodendri and Coptidis rhizome) reduced the accumulation of 
extracellular matrix in the kidney, decreasing the levels of TGF-β1, ICAM-1, fibronectin and 
improving renal function [250]. Administration of diosmin, a flavonoid derivative, inhibited NF-κB 
signaling, and reduced renal levels of proinflammatory cytokines and oxidative stress in an alloxan-
induced DN model [251]. On the other hand, selective blockade of IκB kinase (IKK) complex using 
the IKKα/β inhibitors (BAY 11-7082, parthenolide), IKKγ NBD inhibitory peptide, and BCR-ABL 
tyrosine kinase inhibitor (nilotinib) also had renoprotective effects in experimental models by 
reducing NF-κB activation, cytokine levels and oxidative stress and improving antioxidant defenses 
[252–255]. Recently, we have observed that inhibition of heat shock protein 90, a molecular chaperone 
required for stabilization/activation of IKK complex, led to a decreased expression of 
proinflammatory NF-κB target genes and ameliorated albuminuria, renal inflammation and fibrosis 
in diabetic mice [256]. In the clinical setting, bindarit an anti-inflammatory small compound that 
inhibits p65 and p65/p50-mediated CCL2 transcription, is being evaluated as a potential therapy for 
DN in association with irbesartan, but the results of this phase II clinical study have not yet been 
published (NCT01109212). However, it is necessary to consider the complexity of the signaling 
pathway associated with NF-κB and the diversity of the processes modulated by this transcription 
factor, which could complicate its use as a therapeutic target in DN. 
5.5. JAK/STAT 
The Janus kinases (JAK) family is comprised of four JAK tyrosine kinase receptors (JAK1, JAK2, 
JAK3, and TYK2), while seven members of the signal transducers and activators of transcription 
(STAT) family have been identified (STAT1-4, 5a, 5b and 6) [257]. These transcription factors can 
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homo- or hetero-dimerize and activate the transcription of proinflammatory target genes [258]. 
Although JAK/STAT signaling actions are mainly regulated by phosphorylation of tyrosine and 
serine residues, “nonphosphorylated STAT” functions have also been described by several authors, 
as well as the epigenetic regulation of JAK without STATs mediation [259,260]. Unlike other signaling 
pathways, the regulation of the JAK/STAT is recognized for its simplicity, nevertheless, the wide 
capacity to interrelate with other cell signaling pathways such as PI3K/Akt/mTOR and MAPK/ERK 
axis, complicate their intracellular activity [261,262]. 
Among the various actions attributed to the JAK/STAT pathway, its involvement in 
inflammatory-based diseases appears to be inherent. Due mainly to being a major effector pathway 
of cytokines and others inflammatory mediators, modulation of JAK/STAT signaling has resulted in 
significant clinical advances in the oncology field and also in immune disorders such as rheumatoid 
arthritis, systemic lupus erythematosus and psoriasis [257,263].  
JAK/STAT pathway is involved in the pathogenesis of DN [264,265]. Clinical and experimental 
studies demonstrate JAK1-3, STAT1, and STAT3 overactivation in the progression of DN [14,266]. 
Deleterious effects of JAK/STAT overactivation are mainly produced by the gene expression of 
cytokines, chemokines, adhesion molecules, transcription factors, growth factors, extracellular matrix 
proteins, pro-oxidant enzymes and scavenger receptors associated with fatty acid uptake, 
inflammation, oxidative stress, lipid accumulation, lipotoxicity and fibrosis [264,266–268].  
Selective compounds targeting JAK2 (AG-490/tyrphostin)[269], JAK1/2 (/baricitinib) [270,271], 
STAT1 (fludarabine) [272] and STAT3 (nifuroxazide, S3I-201) [273] reduced albuminuria, 
inflammatory infiltrate, renal damage (mesangial expansion, oxidative stress, tubular atrophy, and 
fibrosis) and serum amyloid A in experimental DN. New design compounds such as the 
bromodomain inhibitor MS417 have shown the capacity to directly target acetyl-lysine residues of 
STAT3 and to reduce proteinuria and kidney damage in db/db mice [274]. Heat shock protein 
inhibitor geldanamycin also disrupts JAK/STAT signaling pathway and reduced renal damage in 
diabetic mice [256]. Several oral small-molecule inhibitors targeting JAK proteins (e.g., ruxolitinib, 
tofacitinib and baricitinib) to prevent STAT phosphorylation have been described as potential 
therapeutic targets for clinical use in autoimmune and inflammatory diseases [275]. Results from a 
phase II clinical trial demonstrate the efficacy of baricitinib (JAK1/2 inhibitor) to reduce albuminuria 
and improve inflammatory biomarkers in T2DM patients with high risk of progressive diabetic 
kidney disease [276]. 
The suppressors of cytokine signaling (SOCS) proteins are described as endogenous regulators 
of the JAK/STAT pathway and, therefore, a feasible therapeutic strategy for diabetic complications 
[261,266,277]. The SOCS family is comprised of eight members (SOCS1-SOCS7 and CIS), with 
different degrees of homology and variable N-terminal domain. The presence of the kinase inhibitory 
region (KIR) located at the N-terminal region of SOCS1/3 has a powerful regulatory action on JAK 
activity and offers an opportunity to develop novel selective kinase inhibitors mimicking KIR effect 
[278]. Optimization of endogenous protective resources through peptidomimetics of SOCS1 could 
have therapeutic advantages associated with the adverse effects observed in treatments with JAK 
inhibitors [276] (e.g., anemia); however, for this objective, it is necessary to carry out efficacy and 
safety studies in humans [279]. In the diabetes context, our findings demonstrate that SOCS1 
mimetics prevent the development of retinopathy and atherosclerosis in mice [280,281]. Different 
SOCS1/3 delivery systems (adenovirus and cell-permeable peptide) alleviate the albuminuria and 
pathological renal features observed in experimental diabetic models, reducing renal inflammation, 
oxidative stress, and glomerular and interstitial fibrosis [261,266,282,283]. In summary, JAK/STAT 
activation is a key cell-signaling pathway in DN. Targeting JAK/STAT/SOCS axis could be a selective 
treatment in DN patients and high inflammatory risk. 
5.6. Protein Kinase C 
Hyperglycemia activates metabolic pathways through the protein kinase C (PKC), a family of 
enzymes widely described in DN progression [8]. In DN, hyperglycemia-mediated PKCβ and PKCδ 
activation in the renal cortex leads to subsequent activation of NF-κB and release of IL-6, and TNF-α 
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by endothelial and mesangial cells [284,285]. Genetic deletion of PKCβ and PKCδ decreased renal 
hypertrophy, podocyte apoptosis, endothelial dysfunction, fibrosis, and proteinuria in diabetic mice 
[285,286]. Similarly, pharmacological inhibition of PKCβ isoform with ruboxistaurin reduced 
glomerular TGF-β expression and decreased fibronectin and collagen IV deposition fibrosis in 
experimental DN [287,288]. This approach also provided renoprotective effects in several clinical 
trials on patients with diabetes or diabetic complications [289] (NCT00297401; NCT00044421).  
5.7. Nrf2 
Nrf2 (nuclear factor (erythroid-derived 2)-like 2) is a crucial protein in redox balance. Its 
activation triggers a powerful antioxidant response by synthesizing more than 250 genes [290]. 
Oxidative stress is closely linked to inflammation in diabetes mellitus and DN [291]. Nrf2 activation 
ameliorates pancreatic cell damage and its suppression aggravates cellular death in diabetic mice 
[292]. Treatment with Nrf2 activators, tert-butylhydroquinone (TBHQ) [293], bardoxolone methyl 
analog [294], or sulforaphane [295], reduced expression of proinflammatory cytokines and 
macrophage infiltration in preclinical models of DN. Furthermore, other compounds with the ability 
to promote Nrf2 translocation, such as omentin-1, and natural flavonoids (myricetin, hesperetin, and 
curcumin), improve renal function and reduces proinflammatory cytokine production in DN [296–
299]. Particularly, dietary supplementation with curcumin increased the antioxidant capacity, 
reduced microalbuminuria and plasma MDA levels of patients with DN [300,301]. A number of 
clinical trials with Nrf2 inducers have been performed in patients with DN. This is the case of 
bardoxolone methyl, an oral antioxidant drug that activates Nrf2. A first 8-week study with 20 
patients determined that this drug was able to increase the eGFR [302]. The continuation of this 
research, in a phase II study with 227 patients treated during 24 and 52 weeks, determined that this 
effect was maintained over time [303] (NCT00811889). A phase III trial with 2185 patients with T2DM 
and stage 4 CKD confirmed that bardoxolone methyl treatment increased eGFR; however, this study 
was interrupted because bardoxolone methyl treated patients showed an increased risk of 
cardiovascular events [304] (NCT01351675). Increased eGFR remained elevated for up to four weeks 
after cessation of treatment, suggesting a lower risk of end-stage renal disease [305]. Two Japanese 
clinical trials in diabetic patients with CKD are now testing the effectivity of bardoxolone (TSUBAKY 
NCT02316821, and AYAME NCT03550443). After an exploratory study in patients with rare kidney 
diseases (PHOENIX, NCT03366337), ongoing bardoxolone trials are being conducted in patients with 
Alport syndrome (CARDINAL, NCT03019185, and EAGLE, NCT03749447), or are recruiting patients 
with autosomal dominant polycystic kidney disease (FALCON, NCT03918447). 
5.8. p38/MAPK  
P38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPK) 
that participates in several cellular stress responses [306]. Studies in human biopsies and cell cultures 
stimulated with high glucose or AGEs, demonstrated activation of the p38/MAPK pathway in 
podocytes, tubular, and interstitial cells [306,307]. Selonsertib, a MAP3K5 (ASK1) inhibitor and 
sulodexide, a sulfated glycosaminoglycan, ameliorated kidney damage by targeting p38/MAPK in 
T1DM and T2DM preclinical models [308–310]. A phase III clinical trial with selonsertib has been 
recently approved in DN patients (NCT04026165).  
The selected preclinical models targeting inflammatory intracellular signaling pathway and 
clinical trial targeting inflammation in DN are summarized in the Table 2 and Table 3, respectively. 
Table 2. Selected preclinical studies targeting inflammatory intracellular signaling pathways in DN. 










Ameliorates hyperuricemia and reduces IL-1β 
and IL-18 levels. 
[226] 




Nutraceuticals Decreases cytokines NLRP3-dependent. [227] 
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ApoE-/- mice + STZ 
(80 mg/kg) 
Pioglitazone PPARγ agonist 
Restores renal function. Downregulates 
AGEs, RAGEs and cytokines NLRP3-
dependent. 
[228] 
db/db mice MCC950 
Selective NLRP3 
inhibitor 
Ameliorates GBM thickness, podocyte injury 
and renal fibrosis. 
[229] 
db/db mice M920 Pan-caspase 
inhibitor 
Reduces NLRP3-inflammasome (IL-1β, IL-18, 
NLRP3, caspase-1) and profibrotic markers. 
[230] 
TLRs 
eNOS-/- + STZ mice CRX-526 TLR4 antagonist 
Ameliorates histological changes, 
inflammatory and profibrotic markers. [232] 
db/db mice GIT27 TLR4 inhibitor 
Reduces proinflammatory, oxidative stress 




SD + STZ (60 mg/kg) Rapamycin mTOR inhibitor 
Ameliorates histological changes, 
inflammation and fibrotic markers. 
[239] 





Reduces inflammation, oxidative stress and 
profibrotic markers. 
[240] 






Reduces GBM thickening, podocyte damage, 
inflammation, apoptosis and fibrosis markers. 
[241] 
Wistar rats + STZ 
(60 mg/kg) 
Emodin 
Derived from root 
rhubarb 




db/db mice Celastrol 
Celastrus regelii 
root extracts 
Improves lipid accumulation, oxidative stress 
and proinflammatory markers. 
[248] 
db/db mice miR-451 LMP7 modulator 
Decreases histological lesions, inflammation 
and fibrosis markers. 
[249] 
Wistar rats + STZ 
(65 mg/kg) 
Berberine Flavonoid 
Improves systemic and renal cortex 
inflammatory response. 
[250] 





Reduces proinflammatory cytokines and 
oxidative stress markers. 
[252] 
ApoE-/- mice + STZ 




Decreases histological lesions, inflammation 
and fibrosis. 
[254] 






Reduces oxidative stress, inflammation and 
profibrotic marker expression. [255] 
JAK/ 
STAT 




JAK 2 inhibitor Prevents JAK2 and STATs phosphorylation. [269] 




JAK 2 inhibitors 
Ameliorates histological changes, serum 
amyloid A3 plasma and kidney tissue. 
[228,
229] 
SD rats + STZ 
(50 mg/kg) 
Nifuroxazide STAT3 inhibitor 
Diminishes inflammatory and profibrotic 







Attenuates histological changes and STAT3 
activity. 
[274] 






Attenuates renal hypertrophy, inflammation 
and profibrotic markers. 
[282] 






Reduces atherosclerosis, structural changes 


















Ameliorates histological changes, apoptosis 
and Swiprosin-1 expression. 
[288] 
Nrf2 
SD rats + IR injury + 




Ameliorates oxidative stress, inflammation 
and apoptosis. 
[293] 
db/db and C57BL/6 





Reduces body weight, histological changes 
and GBM thickening. 
[294] 






Diminishes inflammation, oxidative stress 
markers, DNA damage and cell death. 
[295] 
SD rats + STZ 
(60 mg/kg) 
Hesperetin Flavonoid Ameliorates histological changes, inhibition 
AGEs/RAGE axis and inflammation. 
[296] 
C57BL/6 + STZ 
(50 mg/kg) and Nrf2 
knockdown mice 
Myricetin Flavonoid 
Mitigates inflammation, oxidative stress and 
fibrosis markers. [297] 
db/db mice Omentin-1 Adipokine 
Reduces proinflammatory cytokines and 
oxidative stress markers. 
[298] 
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SD rats + STZ 
(55 mg/kg) 
Curcumin Flavonoid 
Lipid accumulation, angiogenesis, profibrotic 









Ameliorates histological changes, 
inflammatory and profibrotic markers. 
[308] 




OLETF rats Sulodexide Sulfated GAGs 
Reduces histological changes, urinary VEGF 
and profibrotic markers. 
[310] 
Abbreviations: STZ: streptozotocin; SD: Sprague Dawley; OLEFT: Otsuka Long-Evans Fatty Tokushima, NBD: NEMO-
binding domain; SOCS: suppressor of cytokine signaling; TBHQ: tert-butylhydroquinone; ACEi: angiotensin-converting 
enzyme inhibitor; PPARγ: peroxisome proliferator-activated receptor gamma; XO: xanthine oxidase; LMP7: low-molecular 
mass protein-7; NEMO: NF-κB essential modulator; BET: bromodomains and extraterminal motif; BRD4: bromodomain 
containing 4: ASK1: apoptosis signal-regulating kinase 1; GAGs: glycosaminoglycans: GBM: glomerular basal membrane. 
Table 3. Selected clinical trials targeting inflammation in DN. 
Target Compound Enrollment Phase Status 1stor 2nd Outcome Identification 
Chymase inhibitor BAY1142524 Fulacimstat 152 2 C UACR NCT03412006 
VAP-1 inhibitor ASP8232 55 2 C AE—UACR NCT02218099 





165 2 C Albuminuria—eGFR NCT02251067 
CCL2 inhibitor AF2838 Bindarit 100 2 C UACR NCT01109212 
CCL2 inhibitor Spiegelmer® NOX-E36 76 2 C UACR NCT01547897 
CCR2 inhibitor Propagermanium 45 2 A UACR—eGFR NCT03627715 
CCR2 inhibitor CCX140-B 332 2 C UACR NCT01447147 
CCR2/5 antagonist PF-04634817 226 2 C UACR NCT01712061 
CCR2/5 antagonist BMS-813160 319 2 T UACR NCT01752985 
PDE inhibitor Pentoxifylline 196 4 R eGFR NCT03664414 
PDE inhibitor Pentoxifylline 2510 4 A Death—ESRD—UACR NCT03625648 







37 2 C 

















60 2 C UACR NCT01774981 
JAK2 inhibitor Baricitinib 130 2 C UACR—eGFR NCT01703234 
PKCβ Inhibitor Ruboxistaurin 20 3 C UACR NCT00297401 
NRF2 inducer Bardoxolone Methyl 1323 3 A eGFR or ESRD NCT03550443 
NRF2 inducer Bardoxolone Methyl 2185 3 C ESRD or death NCT01351675 
NRF2 inducer Bardoxolone Methyl 216 2 C AE—eGFR NCT02316821 
Anti-inflammatory 
inhibitor 
Colchicine 160 NA A UACR NCT02035891 
Sulfated GAGs KRX-101 Sulodexide 1248 4 T ESRD—UACR NCT00130312 
ASK-1 inhibitor GS-4997 Selonsertib 3300 3 A eGFR—ESRD NCT04026165 
Abbreviations: A: active; AE: adverse effects; C: completed; NA: not applicable; NR: not yet recruiting; R: recruiting; T: 
terminated; U: unknown. UACR: urinary albumin creatinine ratio; eGFR: estimated glomerular filtration rate; ESRD: end-stage 
renal disease; MACE: major adverse cardiovascular events; ERPF: effective renal plasma flow. 
6. Novel Antidiabetic Drugs with Anti-Inflammatory Actions in DN 
Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce renal tubular glucose reabsorption, 
decreasing diabetes-associated hyperglycemia [311]. Recent clinical trials have demonstrated that 
new class of oral glucose-lowering therapy improved renal and cardiovascular outcomes of T2DM 
patients [312,313]. Recent data have also suggested that SGLT2 inhibitors (SGLT2i) possess beneficial 
actions against inflammatory response in DN. Preclinical models Akita or db/db mice treated with 
dapagliflozin reduced macrophage infiltration in the kidney and decreased inflammatory factors, 
such as TGF-β, CCL2, osteopontin, and ICAM-1 [314]. In db/db mice, the use of empaglifozin reduced 
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renal inflammation determined by the reduction of NF-κB, CCL2, IL-6 levels and immune cell 
infiltration [315]. In the clinical field, some studies were developed about the role of SGLT2i in 
diabetic patients. The EMPA-REG OUTCOME (NCT01131676) trial in T2DM patients at high risk of 
CVD, described that the treatment with empagliflozin diminished the incidence DN and the loss of 
renal function [312]. The CANTATA-SU (NCT00968812) study in T2DM patients treated with 
metformin and canagliflozin, showed a reduction in TNFR1, IL-6, metalloproteinase-7 and 
fibronectin-1 levels, suggesting that canagliflozin contributes to reverse molecular processes related 
to inflammation, extracellular matrix turnover and fibrosis [316]. 
Another pillar of current treatment for diabetes is based on incretin modulators [317]. Dipeptidyl 
peptidase-4 inhibitors (DPP4i) are effective for the treatment of residual proteinuria in DN, a fact that 
is evidenced in a recent meta-analysis of the effects of sitagliptin in T2DM patients [318]. Sitagliptin 
also display in vitro and in vivo nephroprotective actions, including antioxidant [319,320], 
lipotoxicity-mediated inflammation [321] and antifibrotic actions [322].  
GLP-1 receptor agonists (GLP-1 RA) are used in the metabolic control of obesity and T2DM 
patients because they enhance glucose-dependent insulin synthesis and secretion, proliferation of β-
cells, inhibition of β-cells apoptosis, delay of gastric emptying and regulation of appetite by satiety-
effects with body weight reduction [323–325]. GLP-1 RA reduces albuminuria and histological renal 
damage [326], and downregulates genes related to inflammation (NF-κB, TNF-α, MCP-1) [327], 
oxidative stress (Nox4 and subunits gp91phox, p22phox, p47phox) [328], de novo 
lipogenesis/lipotoxicity (SREBP-1; ABCA1) [329] and fibrosis (α-SMA, fibronectin, collagen I) [330]. 
These renoprotective effects observed in T2DM and CKD patients have been validated by four major 
clinical trials AWARD-7 [331], LEADER [332], SUSTAIN-6 [333] and ELIXA [334]. In brief, these novel 
antidiabetic drugs have had a tremendous impact on the treatment of cardiovascular and renal 
complications of diabetic patients, there exist hundreds of publications, and they have been 
incorporated as recommendations in all clinical guides (Table 4). 
Table 4. Novel antidiabetic drugs with anti-inflammatory actions in patients with DN. 
Target Compound Enrollment Phase Status 1st or 2nd Outcome Identification 
SGLT2i Empaglifozin 70 4 R Albuminuria—eGFR NCT04127084 
SGLT2i Empaglifozin 7064 3 C MACE and UACR NCT01131676 
SGLT2i + DPP-4i Empaglifozin + Linagliptin 66 4 R eGFR—UACR NCT03433248 
SGLT2i + GLP-1 
RA 
Empaglifozin + Semaglutide 80 4 NR Albuminuria—eGFR NCT04061200 
SGLT2i Canagliflozin 4401 3 C eGFR—ESRD NCT02065791 
SGLT2i Canagliflozin 300 3 A eGFR—UACR NCT03436693 
SGLT2i Canaglifozin 1452 3 C HbA1c change NCT00968812 
SGLT2i Dapagliflozine 44 4 C eGFR—ERPF—UACR NCT02682563 
DPP-4i Linagliptin 48 4 C eGFR—ERPF NCT02106104 
DPP-4i Linagliptin 6991 4 C MACE—eGFR NCT01897532 
DPP-4i Alogliptin 5380 3 C MACE NCT00968708 
DPP-4i Saxagliptin 18206 4 C MACE NCT01107886 
DPP-4i Sitagliptin 14671 3 C MACE—eGFR NCT00790205 
GLP-1 RA Lixisenatide 40 4 C eGFR—ERPF NCT02276196 
GLP-1 RA Exenatide 92 4 C Albuminuria NCT02690883 




GLP-1 RA Liraglutide 9341 3 C MACE and UACR NCT01179048 




GLP-1 RA Lixisenatide 6068 3 C MACE—UACR NCT01147250 
Abbreviations: A: active; C: completed; NR: not yet recruiting; R: recruiting; UACR: urinary albumin creatinine ratio; eGFR: 
estimated glomerular filtration rate; ESRD: end-stage renal disease; MACE: major adverse cardiovascular events; ERPF: 
effective renal plasma flow 
7. Perspectives and Conclusions 
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DN is one of the most leading causes of CKD/ ESRD. Established treatment for patients with 
diabetes includes control of blood glucose, cholesterol and hypertension, but provide incomplete 
protection against ESRD and cardiovascular risk. There is, therefore, an urgent need to apply more 
effective therapies for patients with DN. 
Targeting inflammation may be useful in the prevention and treatment of DN. In this sense, the 
inhibition of IL-1β activity (gevokizumab, anakinra and canakinumab) and the blockade of CCL2 
(AF2838) and their receptors CCR2/CCR5 (CCX140-B, PF-04634817, BMS-813160) open a new horizon 
for the employment of anti-inflammatory therapies in patients DN, including those with 
cardiovascular risk. The blockade of some adhesion molecules (Galectin-3, αVβ3) has also provided 
beneficial effects in DN. NLRP3 inflammasome and its related cytokine IL-18 have emerged as 
important inflammatory molecules involved in the progression of DN. However, no compounds 
targeting inflammasome components have been yet tested in clinical trials. Although Th17 response 
has gained attention in the last years, there are controversial results about its role in DN. On the other 
hand, oxidative stress is closely related to inflammation in DN. Several clinical reports suggest that 
activation of the Nrf2 pathway, mainly with bardoxolone, may be of interest. 
As discussed in this review, several urinary and plasma inflammatory biomarkers have been 
examined at early and advanced stages DN. These biomarkers can be associated to glomerular and 
tubular damage, oxidative stress, and fibrosis development [335]. Moreover, some inflammatory 
markers (TNFα, IL-6 and CCL2) and adipokines (resistin, visfatin and leptin) detected in the saliva 
of T2DM patients could have a prognostic value on the progression of DN, given their high 
correlation with serum/urinary inflammatory markers [336,337]. The refinement of -omic techniques 
and novel bioinformatic platforms predict an exponential growth in this area, both in the diagnosis 
and categorization of DN. 
In conclusion, emerging therapies for DN are focused on the modulation of inflammatory 
pathways that control the functional and structural abnormalities in DN. Compounds targeting some 
chemokines and their receptors, cytokines, NF-κB, NLRP3 inflammasome, PI3K/Akt and JAK/STAT 
pathways, and the Nrf2-regulated antioxidant defense have shown remarkable efficacy in preclinical 
studies. In this regard, some incipient clinical trials (e.g., baricitinib, canakinumab) have afforded 
promising results in patients with DN. Therefore, although recent clinical trials with SGLT2i and 
GLP-1 RA have provided beneficial effects in patients with DN, additional specific anti-inflammatory 
strategies may be of special interest to further reduce residual proteinuria and progression to renal 
failure. Further research is needed to find the balance between the benefits and potential risks of these 
incoming therapies, and to identify the subgroups of patients most likely to benefit from them. 
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Abbreviations 
ABCA1 ATP binding cassette transporter A1 
ACEi Angiotensin-converting -enzyme inhibitors 
AGEs Advanced glycation end-products 
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Akt Protein kinase B 
ApoE Apolipoprotein E 
AP-1 Activator protein-1 
ARBs Angiotensin Receptor Blockers 
ASK1 Apoptosis signal-regulating kinase 1 
BMP-7 Bone morphogenetic protein 7 
BTBR Black and tan brachyuric  
BUN Blood urea nitrogen 
CASP1 Caspase-1 
CCL11 Chemokine-CC motif ligand 11 
CCL2 Chemokine-CC motif ligand 2 
CCL5 Chemokine-CC motif ligand 5 
CCR2 C-C chemokine receptor 2 
CCR5 C-C chemokine receptor 5 
CD206/ MRC1 Mannose receptor 
CD4+ Cluster of differentiation 4+ 
CD74 Cluster of differentiation 74 
CD8+ Cluster of differentiation 8+ 
CKD Chronic kidney disease 
Col IV Collagen IV 
CVD Cardiovascular Disease 
CX3CL1 Fractalkine 
CX3CR1 Fractalkine receptor 
CXCL1 Chemokine (C-X-C motif) ligand 1 
CXCL10 Chemokine (C-X-C motif) ligand 10 
CXCL12 Chemokine (C-X-C motif) ligand 12 
CXCL16 Chemokine (C-X-C motif) ligand 16 
CXCL5 Chemokine (C-X-C motif) ligand 5 
CXCL8 Chemokine (C-X-C motif) ligand 8 
CXCL9 Chemokine (C-X-C motif) ligand 9 
CXCR4 C-X-C chemokine receptor type 4 
db/db Diabetic/diabetic 
DCs Dendritic cells 
DN Diabetic nephropathy 
DNA Deoxyribonucleic acid 
DPP4i Dipeptidyl peptidase-4 inhibitors 
eGFR Estimated glomerular filtration rate 
EMT Epithelial to mesenchymal transition 
EndMT Endothelial to mesenchymal transition 
ERK 1/2 Extracellular Signal-Regulated Kinase 1/2 
ESRD End-stage renal disease 
FGF1 Acidic fibroblast growth factor 
GBM Glomerular basement membrane 
GLP-1 Glucagon-Like Peptide 1 
GLP-1 RA GLP-1 receptor agonists 
GSK-3β Glycogen synthase kinase 3β 
HbA1c Hemoglobin A1c 
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HK-2 Human kidney 2 cells 
HO-1 Heme Oxygenase 1 
ICAM-1 Intercellular adhesion molecule-1 
IFN-γ Interferon-γ 
IgG Immunoglobulin G 
IgM ImmunoglobulinM 
IKKα/β/γ IκB kinase α/β/γ 
IL-10 Interleukin-10 







IP-10 Interferon-inducible protein 10 
JAK Janus Kinase/ Just Another Kinase 
KIR Kinase inhibitory region 
KRIS Risk inflammatory signature 
LDL Low Density Lipoprotein 
Ly6C Lymphocyte antigen 6C 
mAb Monoclonal Antibody 
MAP3K5  Mitogen-activated protein kinase 5 
MAPK Mitogen-Activated Protein Kinase 
MDA Malondialdehyde 
MEK Mitogen-activated protein kinase kinase 
MIF Macrophage migration inhibitory factor 
MIP-1 Macrophage Inflammatory Protein-1 
MMP Matrix metalloproteinase 
mTOR Mammalian target of rapamycin 
NADPH Nicotinamide adenine dinucleotide phosphate hydrogen 
NBD Nucleotide-binding domain 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR Nucleotide-binding oligomerization domain (NOD)-like receptors 
NLRP Pyrin domain-containing protein 
NOD1 Nucleotide -binding oligomerization domain-containing protein 1 
NOD2 Nucleotide -binding oligomerization domain-containing protein 2 
NOX-4 NADPH oxidase 4 
Nrf2 Nuclear factor (erythroid-derived 2)-like 2 
Ob         obese 
P38/MAPK p38 mitogen-activated protein kinase 
p53 Cellular tumor antigen p53 
PDGF Platelet derived growth factor 
PI3K Phosphatidylinositol 3-kinase 
PKC Protein kinase C 
PPAR-γ Peroxisome proliferator-activated receptor-γ 
PTEN Phosphatase and tensin homolog 
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PTX3 Pentraxin 3 
RAAS Renin–-angiotensin–-aldosterone system 
ROS Reactive Oxygen Species 
SGLT2 Sodium-glucose cotransporter-2 
SGLT2i SGLT2 inhibitors 
sICAM-1   Soluble intercellular adhesion molecule-1 
Smad Mothers against decapentaplegic homolog 
SOCS Suppressors of cytokine signaling 
SREBP-1 Sterol regulatory element binding transcription factor 1 
STAT Signal Transducer and Activator of Transcription 
sTWEAK Soluble TNF-related weak inducer of apoptosis 
STZ Streptozotocin 
T1DM Type 1 and type 2 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
TBHQ Tert-butylhydroquinone 
TGF-β Transforming growth factor-β 
Th1 T helper cell type 1 
Th17 T helper cell type 17 
Th2 T helper cell type 2 
TLRs Toll-like receptors 
TNF-α Tumor necrosis factor-α 
TNFR1 Tumor necrosis factor receptor 1 
TNFR2 Tumor necrosis factor receptor 2 
Tregs Regulatory T cells 
TYK2 Tyrosine kinase 2 
UACR Urine albumin to creatinine ratio 
VAP-1 Vascular adhesion protein-1 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 
ZSF1 Zucker Diabetic Fatty 1 
α-SMA α-smooth muscle actin 
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